SIA
OBIO icon

SkyView Investment Advisors’s Orchestra BioMed OBIO Stock Holding History

SkyView Investment Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,284
Closed -$63K – 328
2024
Q3 		$63K Sell
12,284
-7,716
-39% -$50.4K 0.01% 244
2024
Q2 		$163K Buy
+20,000
New +$116K 0.03% 261

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SkyView Investment Advisors's OBIO Position: Q4 2024 in Review

SkyView Investment Advisors sold out of Orchestra BioMed (OBIO) in Q4 2024, closing a stake of 12,284 shares — an estimated $63K sold.

SkyView Investment Advisors first reported a position in OBIO in Q2 2024 and held it in 2 quarters. The position peaked at $163K in Q2 2024. 54 funds tracked by Wall St. Rank hold OBIO as of Q4 2024.

  • SkyView Investment Advisors reported no remaining Orchestra BioMed position as of Q4 2024 after selling out during the quarter.
  • SkyView Investment Advisors sold 12,284 Orchestra BioMed shares in Q4 2024, an estimated $63K.
  • SkyView Investment Advisors first reported a position in Orchestra BioMed in Q2 2024 and held it in 2 quarters.
  • SkyView Investment Advisors's Orchestra BioMed position peaked at $163K in Q2 2024.
  • 54 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2024.

Based on SkyView Investment Advisors's 13F filing for Q4 2024, filed 2 Jun 2025.